Market capitalization | $1.97b |
Enterprise Value | $1.67b |
P/E (TTM) P/E ratio | 13.05 |
EV/FCF (TTM) EV/FCF | 7.52 |
EV/Sales (TTM) EV/Sales | 2.24 |
P/S ratio (TTM) P/S ratio | 2.64 |
P/B ratio (TTM) P/B ratio | 2.73 |
Revenue growth (TTM) Revenue growth | 20.62% |
Revenue (TTM) Revenue | $744.85m |
As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.
9 Analysts have issued a Harmony Biosciences Holdings forecast:
9 Analysts have issued a Harmony Biosciences Holdings forecast:
Mar '25 |
+/-
%
|
||
Revenue | 745 745 |
21%
21%
|
|
Gross Profit | 560 560 |
20%
20%
|
|
EBITDA | 219 219 |
4%
4%
|
EBIT (Operating Income) EBIT | 195 195 |
4%
4%
|
Net Profit | 153 153 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Head office | United States |
CEO | Jeffrey Dayno |
Employees | 268 |
Founded | 2017 |
Website | www.harmonybiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.